of determining glucose with a reagent strip, may reduce the haematocrit effect even further and also produce a result in less than 30 sec. ' The Nova Stat Profile 5 blood gas analyser from Bayer Diagnostics measures glucose in whole blood and suffers very little effect from haematocrit. It contains a glucose module consisting of glucose oxidase bound to a membrane and a hydrogen peroxide-sensitive electrode. The membrane excludes large molecules from the measurement system allowing measurement of glucose in the aqueous phase of the sample. This is the same principle as used in the YSI instrument but unlike the YSI there is no dilution step within the instrument. In a manner analogous to the difference between direct and indirect ionsensitive electrodes the Nova instrument, unlike the YSI, is not affected by the presence of nonaqueous material (i.e. red cell components) in the sample. No significant correlation between changes in haematocrit and measured glucose levels was seen in my experiments using the Nova instrument (see table 1) although a slight negative effect of increasing haematocrit has been reported previously."
Author's reply Dr Jones's letter raises a number of interesting points. I agree that the Boehringer Accutest/ Accutrend is only slightly affected by haematocrit; however, while the Glucostix/Glucometer 2 may have been superseded by Glucofilm/Glucometer 3 in Australia, it certainly has not in the UK, since Bayer decided not to market the latter system here.
Dr Jones says that the Nova and YSI systems are analogous to direct and indirect ion-selective electrodes, respectively. I think this is a false analogy or, at best, it only partially describes the situation. Ion-selective electrodes respond to the concentration (strictly activity) of ions in the water of the sample. Discrepancies between direct and indirect methods arise when the sample contains unusually large amounts of substances such as protein or lipids, which occupy a larger proportion of the sample than usual, thus reducing the proportion occupied by water. The concentration of ion in the water remains the same, but the total amount of ion in the sample is reduced. If the measuring technique involves dilution, the dilution of the ion in water is then greater than is apparent from the known sample and diluent volumes and leads to a discrepancy in results compared with a direct-reading technique. Of course, the error arises because, when calibrating the assay, assumptions are made about the amount of water in the sample and in this case are incorrect.
In the case of blood glucose, there is an element of the above situation owing to plasma being about 93% water and red cell contents about 71% and the Nova results appear to be molalities (mmol/kg of water).' However, when whole blood is diluted without lysis, as in the YSI method, the lowered extracellular glucose concentration will cause intracellular glucose to diffuse out of the red cells and thus become accessible for measurement. If in the directmeasuring system, this movement of glucose out of the red cells does not take place, then the measurement would appear to be purely of plasma water glucose even though whole blood is being presented to the system. It would not be altogether surprising, therefore, if the haem atocrit effect were small. On the other hand, Fogh-Andersen et al. did observe a significant haematocrit effect on the Nova. ' Incidentally, I think there is a basic flaw in the way Dr Jones investigated the Nova analyser. He made adjustments to the haematocrit Letters of a blood sample, presumably by recombining different proportions of plasma and red cells, but he then added glucose to a level of 11 mmoIlL. He does not explain how this was done, but he seems to have assumed that the glucose would equilibrate between red cells and plasma. This may well be so, but if it remained mainly in the plasma, it would tend to counterbalance any haematocrit effect and might explain why he observed none.
The HemoCue differs in that the red cells are lysed. Therefore, glucose release should be more rapid and complete than in the YSI technique. In this respect it is similar to the APEC analyser (UK agents Vital Scientific Ltd, Sussex, UK) in which whole blood and plasma are claimed to give very similar results with no significant haematocrit effect.
The Analox GM glucose analyser can be used to measure glucose in plasma, in whole blood with intact red cells or in lysed whole blood. the manufacturers report that intact whole blood gives results 12 to 140/0 lower than plasma and lysed blood shows intermediate values.
It seems that methods using lysed whole blood give higher results than those using intact whole blood. While cellular constituents other than glucose may interfere in some methods, lysis may also release more glucose than the dilution methods are able to in the limited time before measurement takes place. Further work is therefore needed to resolve this issue.
In conclusion, the situation is much more complex than Dr Jones's comments suggest. It is further complicated by the absence of a suitable independent reference method for whole blood systems and by the way in which systems are adjusted to give results expressed as whole blood glucose even when plasma glucose is actually measured. Use of free l3-hCG in Down's syndrome screening
We would like to comment on a number of points raised by Kevin Spencer and his colleagues in their recent paper on the use of free~-hCG in Down's syndrome screening.' 77% detection rate for Down's syndrome It was concluded in the abstract that freẽ -hCG was the marker of choice in Down's syndrome screening and that when used early in the second trimester of pregnancy (at 14-16 weeks) in combination with o-fetcprotein (AFP) and maternal age, it would allow the detection of 77% of cases of Down's syndrome. This 77% estimate is meaningless alone; the corresponding false-positive rate must be specified.
The cited 77% detection rate is based on a subset of the data; attention was focused on the half of cases of Down's syndrome presenting at 14-16 weeks' gestation (Table 9 in Spencer et al.) . 1 The results for the remaining half of the cases (at 17or more weeks' gestation) were reported as yielding a smaller detection rate of 54%, a difference that was interpreted by the authors as showing that the test performs better before 17 weeks than afterwards. The higher detection rate in the earlier period may have been associated with a higher false-positive rate-countering the apparent advantage. Again, the data cannot be interpreted properly without specifying the corresponding false-positive rates. The percentages are inconsistent with data shown in their Fig. 2 which show that the average levels of free~-hCG, and therefore the corresponding detection rates, are similar for the two gestational periods. From this figure, we have calculated that the percent age of cases equal to or greater than 2'0 MoM was 60% at 14-16 weeks of gestation, and 70% at 17 weeks or more, proportions that are directionally the opposite of those claimed in their Table 9 . It is possible that the authors' conclusion that screening performance is better in the early gestational period than in the later one is confounded by maternal age and therefore not attributable to free~-hCG. Women seen earlier may be somewhat older, on average, than those who were seen later and for this reason tend to have higher risk estimates, leading to both a higher detection rate and a higher false-positive rate than the overall group.
